NEW YORK (GenomeWeb News) – Agilent Technologies and WiCell said today they are teaming up to offer comparative genomic hybridization plus single nucleotide polymorphism microarray analysis services using the Agilent SurePrint G3 Human Genome CGH+SNP Microarray.
The microarray detects copy number changes by both SNP and CGH while simultaneously delivering copy-neutral change information such as loss or absence of heterozygosity, the companies said. They added that the assay maintains the high-resolution quality achieved with CGH-only microarrays.
"WiCell's considerable experience and know-how in cytogenetic analysis and their large CGH dataset for embryonic and induced pluripotent stem cells partners well with Agilent's technology to enable robust detection capabilities vital for research and commercial development," Kathleen Shelton, senior director of genomics marketing at Agilent, said in a statement.
Financial and other terms of the partnership were not disclosed.
WiCell is based in Madison, Wis., and offers cytogenetic testing of mouse and human embryonic stem cells and induced pluripotent stem cells.